Mitogen-activated protein kinase-activated protein kinase 2 (MAPKAPK2) (MK2)

Mitogen-activated protein kinase-activated protein kinase 2 (MAPKAPK2), commonly known as MK2, is a serine/threonine kinase that acts as a critical downstream effector of the p38 mitogen-activated protein kinase (MAPK) pathway (UniProt P49137). It plays a central role in the inflammatory response by regulating the production of pro-inflammatory cytokines, such as TNF-alpha and IL-6, primarily through the stabilization of their mRNA transcripts via phosphorylation of tristetraprolin (TTP) (PubMed: 23747517). Beyond inflammation, MK2 is involved in cell cycle regulation, DNA damage response, and actin remodeling (UniProt P49137). Therapeutic strategies targeting MAPKAPK2 include small molecule inhibitors that block its kinase activity and RNA interference (RNAi) molecules, such as ARO-MK2, which specifically target the MAPKAPK2 mRNA to reduce protein expression (Arrowhead Pharmaceuticals; ClinicalTrials.gov NCT04050930). These approaches are being investigated for the treatment of chronic inflammatory diseases like rheumatoid arthritis and psoriasis, as well as certain cancers where MK2 signaling is dysregulated (PubMed: 23747517). Targeting the mRNA directly via RNAi offers a potential advantage in durability and specificity compared to traditional small molecule kinase inhibitors (Arrowhead Pharmaceuticals). Clinical development of MK2-targeted therapies has historically faced challenges with systemic toxicity, but mRNA-targeted approaches aim to improve the therapeutic index by reducing protein levels at the source (PubMed: 23747517).

Other names

MAPKAPK2MAPK-activated protein kinase 2MAPKAP kinase 2MK-2MAPKAP-K2

RNA interference (RNAi) mediated degradation of MAPKAPK2 mRNA transcripts; ATP-competitive or non-competitive inhibition of the MAPKAPK2 kinase domain.